Brain stem glioma

disease
On this page

Also known as brain stem neuroglial neoplasmbrain stem neuroglial tumorbrain stem neuroglial tumourbrainstem gliomabrainstem malignant gliomabrainstem neuroglial neoplasmbrainstem neuroglial tumorbrainstem neuroglial tumourdiffuse brainstem gliomaglioma of brain stemglioma of brainstemglioma of the brain stemglioma of the brainstemmalignant glioma of brainstem

Summary

Brain stem glioma (MONDO:0002911) is a cancer (an umbrella term covering 5 Mondo subtypes) and 28 clinical trials. Top therapeutic interventions include bevacizumab, mebendazole, and temozolomide. A subtype of brainstem cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Classification: Cancer
  • Umbrella term: 5 Mondo subtypes
  • Clinical trials: 28

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical namebrain stem glioma
Mondo IDMONDO:0002911
EFOEFO:1000142
DOIDDOID:4202
NCITC8501
SNOMED CT444545003
UMLSC0677865
MedGen195650
GARD0023297
Anatomy (UBERON)UBERON:0002298
Is cancer (heuristic)yes

Also known as: brain stem glioma · brain stem neuroglial neoplasm · brain stem neuroglial tumor · brain stem neuroglial tumour · brainstem glioma · brainstem malignant glioma · brainstem neuroglial neoplasm · brainstem neuroglial tumor · brainstem neuroglial tumour · diffuse brainstem glioma · glioma of brain stem · glioma of brainstem · glioma of the brain stem · glioma of the brainstem · malignant glioma of brainstem

Disease family

An umbrella term covering 5 Mondo subtypes.

Classification path: disease by etiologic mechanism › cancer or benign tumorneoplastic disease or syndromeneoplasmcancernervous system cancercentral nervous system cancerbrain cancerinfratentorial cancer › brainstem cancer › brain stem glioma

Related subtypes (1): childhood brain stem neoplasm

Subtypes (5): adult brainstem glioma, brain stem astrocytic neoplasm, brain stem ependymoma, childhood brain stem glioma, brain stem glioblastoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 28.

Phase distribution (across all retrieved trials)

PhaseTrials
PHASE19
PHASE26
Not specified6
PHASE1/PHASE23
PHASE32
PHASE2/PHASE31
EARLY_PHASE11

Top trials by phase / activity

NCTPhaseStatusTitle
NCT02864888PHASE3NOT_YET_RECRUITINGEffect of Antineoplaston Therapy on the QT/QTc Interval In Subjects With Diffuse, Intrinsic, Brainstem Glioma
NCT02887040PHASE3NOT_YET_RECRUITINGStudy of Antineoplaston Therapy + Radiation vs. Radiation Only in Diffuse, Intrinsic, Brainstem Glioma
NCT01236560PHASE2/PHASE3COMPLETEDVorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma
NCT00840047PHASE2ACTIVE_NOT_RECRUITINGMethionine PET/CT Studies In Patients With Cancer
NCT00003459PHASE2COMPLETEDAntineoplaston Therapy in Treating Patients With Brain Stem Glioma
NCT00879437PHASE2COMPLETEDValproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma
NCT01095094PHASE2TERMINATEDRitonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma
NCT01118377PHASE2COMPLETEDA Study of Capecitabine (Xeloda®) and Concomitant Radiation Therapy in Children With Newly Diagnosed Brainstem Gliomas
NCT01514201PHASE1/PHASE2COMPLETEDVeliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas
NCT01756989PHASE2COMPLETEDANGIOCOMB Antiangiogenic Therapy for Pediatric Patients With Diffuse Brain Stem and Thalamic Tumors
NCT01837862PHASE1/PHASE2COMPLETEDA Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas
NCT01884740PHASE1/PHASE2TERMINATEDIntraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22
NCT04196413PHASE1RECRUITINGGD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas (DIPG) & Spinal Diffuse Midline Glioma(DMG)
NCT00576641PHASE1COMPLETEDImmunotherapy for Patients With Brain Stem Glioma and Glioblastoma
NCT01082926PHASE1COMPLETEDPhase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2
NCT01316809PHASE1COMPLETEDAZD8055 for Adults With Recurrent Gliomas
NCT01502917PHASE1COMPLETEDConvection-Enhanced Delivery of 124I-Omburtamab for Patients With Non-Progressive Diffuse Pontine Gliomas Previously Treated With External Beam Radiation Therapy
NCT03178032PHASE1COMPLETEDOncolytic Adenovirus, DNX-2401, for Naive Diffuse Intrinsic Pontine Gliomas
NCT03355794PHASE1COMPLETEDA Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG)
NCT03392545PHASE1UNKNOWNCombination of Immunization and Radiotherapy for Malignant Gliomas (InSituVac1)
NCT03396575PHASE1TERMINATEDBrain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy Recovery Alone or With Dose-intensified Temozolomide (Phase I)
NCT02976441EARLY_PHASE1WITHDRAWNAutologous Stem Cell Collection and Reinfusion in Newly Diagnosed High Grade Gliomas
NCT01106794Not specifiedRECRUITINGMolecular Analysis of Samples From Patients With Diffuse Intrinsic Pontine Glioma and Brainstem Glioma
NCT07608003Not specifiedRECRUITINGMulticenter Prospective Study on MRI AI Model for Midline Glioma Subtyping and Prognosis:
NCT01117155Not specifiedWITHDRAWNA Pilot Study Evaluating 18F-L-Thymidine (FLT) PET Imaging in Children With Gliomas
NCT03666507Not specifiedCOMPLETEDVegetative Monitoring During Brainstem-associated Surgery
NCT05934630Not specifiedTERMINATEDTesting Cerebrospinal Fluid for Cell-free Tumor DNA in Children, Adolescents, and Young Adults With Brain Tumors
NCT06439849Not specifiedNO_LONGER_AVAILABLESingle Patient Compassionate Use / Expanded Access L-S-Gboxin (Lyophilized Form of S-Gboxin) for the Treatment of Diffuse Midline Glioma

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
BEVACIZUMAB44
MEBENDAZOLE41
TEMOZOLOMIDE41
VALPROIC ACID41
VORINOSTAT41
ANTINEOPLASTON A1032
VELIPARIB32
METHIONINE31
TASADENOTUREV21
AZD-805511
CHEMBL422879401
CHEMBL424819501
CHEMBL123426801
CHEMBL478769901
RACEMETHIONINE-11